Business Context and Reporting Period
Company: Roivant Sciences Ltd.
Filing Type: Form 10-K (Annual Report)
Fiscal Year Ended: March 31, 2026
Business Model: Roivant operates a "Vant" model, creating nimble subsidiaries to develop and commercialize medicines. Key subsidiaries include Priovant (brepocitinib), Immunovant (IMVT-1402), Pulmovant (mosliciguat), and Genevant (LNP technology). The company has no currently approved commercial products following the sale of Dermavant in October 2024.
Key Financial Metrics
| Metric | Year Ended March 31, 2026 | Year Ended March 31, 2025 |
|---|---|---|
| Revenue | $8.3 million | $29.1 million |
| Net Loss (Attributable to Roivant) | $(299.8) million | $(172.0) million |
| Operating Expenses | $1.29 billion | $1.14 billion |
| Research & Development (R&D) | $681.8 million | $550.4 million |
| Cash, Cash Equivalents & Marketable Securities | $4.3 billion | $4.9 billion |
| Accumulated Deficit | $(501.8) million | $116.1 million (Retained Earnings) |
| Share Repurchases | $318.1 million | $1.3 billion |
Note: The 2026 Net Loss includes a significant non-cash gain on litigation settlement of $770.2 million. Without this gain, the operating loss would be substantially higher.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by $20.8 million (72%) to $8.3 million, primarily due to the sale of Dermavant and lower license revenue from Genevant compared to the prior year.
- Increased R&D Spend: R&D expenses increased by $131.4 million (24%) to $681.8 million. This was driven by increased program-specific costs for the Anti-FcRn franchise (including $39.0 million in contractual costs for the discontinuation of batoclimab), mosliciguat, and brepocitinib.
- Gain on Litigation Settlement: A one-time gain of $770.2 million was recognized in 2026 from a settlement with Moderna regarding LNP technology patent infringement. This significantly offset operating losses.
- Discontinued Operations: The sale of Dermavant to Organon in October 2024 resulted in a gain of $373.0 million reported in discontinued operations for the 2025 fiscal year. No discontinued operations were reported for 2026.
- Share Repurchases: Repurchase activity slowed significantly, with $318.1 million spent in 2026 compared to $1.3 billion in 2025. Approximately $890.3 million remains authorized for future repurchases.
Guidance, Outlook, and Management Commentary
- Key Catalysts (2026-2027):
- Brepocitinib (Priovant): FDA decision expected in Q3 2026 for dermatomyositis (DM). Commercial launch expected by September 2026. Phase 3 topline data for non-infectious uveitis expected in 2H 2026.
- IMVT-1402 (Immunovant): Topline data from Phase 2 cutaneous lupus erythematosus and updates on difficult-to-treat rheumatoid arthritis expected in 2H 2026. Registrational trials in Graves' disease expected to report in 2027.
- Mosliciguat (Pulmovant): Phase 2 topline data for pulmonary hypertension associated with interstitial lung disease expected in 2H 2026.
- Strategic Shifts: Immunovant discontinued the development of batoclimab following failed Phase 3 trials for thyroid eye disease in April 2026, focusing resources entirely on IMVT-1402.
- Liquidity: Management states that existing cash, cash equivalents, and marketable securities ($4.3 billion) are sufficient to fund operations for the foreseeable future. No immediate need for additional capital is anticipated.
- Risks: Significant risks include the uncertainty of clinical trial outcomes, regulatory approval timelines, potential disputes with licensors (e.g., HanAll regarding batoclimab), and the impact of new U.S. tariffs on pharmaceutical products effective September 2026.
Investor Verification Checklist
- Moderna Settlement Contingency: Verify the status of the $1.3 billion contingent payment from Moderna, which depends on the outcome of a Section 1498 appeal expected in 2027. This amount is not currently recognized in earnings.
- Batoclimab Discontinuation Costs: Confirm the $42.5 million accrued liability for non-cancelable contractual costs related to batoclimab and ensure no further disputes arise with HanAll Biopharma.
- Brepocitinib FDA Decision: Monitor the FDA PDUFA date in Q3 2026 for dermatomyositis, which is the primary near-term revenue driver.
- Share Repurchase Authorization: Track the remaining $890.3 million repurchase authorization and management's discretion on capital return versus R&D investment.
- Tariff Impact: Assess the potential impact of the new U.S. tariffs on pharmaceutical products (10-100%) scheduled to take effect in September 2026 on manufacturing costs and margins.